Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia

1997337 citationsJournal Article

Authors

Richard C. Eastman

Jonathan C. Javitt · National Institute of Diabetes and Digestive and Kidney Diseases

William H. Herman · Georgetown University

Erik J. Dasbach

Catherine Copley‐Merriman · Pfizer (United States)

William C. Maier · Pfizer (United States)

Fred Dong · Battelle

Diane L. Manninen

Abstract

The incremental effectiveness of treating NIDDM with the goal of normoglycemia is estimated to be approximately $16,000/QALY gained, which is in the range of interventions that are generally considered cost-effective.

Topics & Keywords

Diabetes Treatment and Management Health Systems, Economic Evaluations, Quality of Life Diabetes Management and Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Care

Volume 20, Issue 5, pp. 735-744

DOI: 10.2337/diacare.20.5.735

Field-Weighted Citation Impact: 14.16